Soft Tick Relapsing Fever — United States, 2012–2021

Amy M. Beeson, MD1,2; Anne Kjemtrup, DVM, PhD3; Hanna Oltean, MPH4; Hannah Schnitzler, DVM4; Heather Venkat, DVM5,6; Irene Ruberto, PhD5; Natalie Marzec, MD7; Devon Cozart, MPH8; Leslie Tengelsen, PhD, DVM9; Stephen Ladd-Wilson, MS10; Hannah Rettler, MPH11; Bonny Mayes12; Kelly Broussard, MPH12; Ali Garcia, MPH13; Lisa L. Drake, PhD14; Elizabeth A. Dietrich, PhD1; Jeannine Petersen, PhD1; Alison F. Hinckley, PhD1; Kiersten J. Kugeler, PhD1; Grace E. Marx, MD1 (View author affiliations)

View suggested citation


What is already known about this topic?

Soft tick relapsing fever (STRF) is a rare but serious bacterial disease spread by Ornithodoros ticks. In the United States, acquisition of STRF is associated with rustic cabins, camping, and caves.

What is added by this report?

During 2012–2021, a total of 251 STRF cases were identified in 11 of 12 states where infection is reportable; 55% of patients were hospitalized, and no deaths occurred. The geographic distribution and seasonal pattern of STRF have remained relatively constant since the 1990s.

What are the implications for public health practice?

Persons should avoid rodent-infested structures and rodent habitats, such as caves, in areas where STRF is endemic. Improvements in surveillance, prevention, and diagnosis are needed to prevent STRF-associated morbidity and mortality.

Article Metrics

Views equals page views plus PDF downloads

Related Materials


Soft tick relapsing fever (STRF) (also known as tickborne relapsing fever) is a rare infection caused by certain Borrelia spirochetes and transmitted to humans by soft-bodied Ornithodoros ticks. In the United States, acquisition of STRF is commonly associated with exposure to rustic cabins, camping, and caves. Antibiotic treatment is highly effective for STRF, but without timely treatment, STRF can result in severe complications, including death. No nationally standardized case definition for STRF exists; however, the disease is reportable in 12 states. This report summarizes demographic and clinical information for STRF cases reported during 2012–2021 from states where STRF is reportable. During this period, 251 cases were identified in 11 states. The median annual case count was 24. Most patients with STRF (55%) were hospitalized; no fatalities were reported. The geographic distribution and seasonal pattern of STRF have remained relatively constant since the 1990s. Persons should avoid rodent-infested structures and rodent habitats, such as caves, in areas where STRF is endemic. STRF surveillance, prevention, and control efforts would benefit from a standardized case definition and increased awareness of the disease among the public and clinicians.


Ornithodoros ticks usually inhabit rodent nests and burrows. They can live for decades, and once infected with relapsing fever, Borrelia spp., can transmit the bacteria to humans throughout their lifetime through brief and painless bites that are often not detected. Soft tick relapsing fever (STRF) (also known as tickborne relapsing fever) is caused by infection with various Borrelia spp., each transmitted by a specific Ornithodoros species. STRF is endemic in certain areas in Africa, Asia, Europe, and the Americas. In the United States, two Borrelia species, Borrelia hermsii and Borrelia turicatae, have been confirmed to cause STRF in humans. B. hermsii, spread by Ornithodoros hermsi ticks, is found in mountainous areas of western states at moderate to high elevations and is commonly associated with rustic, rodent-infested cabins. B. turicatae, spread by Ornithodoros turicata, is found in the south-central United States and is often associated with caves.

The clinical syndrome of STRF in humans includes high fever, which can be accompanied by headache, nausea, myalgias, and arthralgias. The initial illness typically lasts approximately 3 days; if untreated, febrile episodes can recur every 7–10 days for two or more cycles, because of the spirochetes’ unique ability to repeatedly evade a host’s immune system (1). Prompt treatment is important to prevent complications; effective antibiotics include doxycycline, beta-lactam antibiotics (e.g., penicillin or ceftriaxone), and azithromycin (2). Rare complications of STRF include neurologic and ocular disease, myocarditis, and acute respiratory distress syndrome (3). Infection during pregnancy can result in pregnancy loss, transplacental transmission, and neonatal death (46).


In 2021, STRF was reportable in 12 states: Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming.* Seven of these states used a case definition during 2012–2021; definitions differed among states. This summary describes cases that were classified as confirmed, probable, or suspected, as well as unclassified cases that met specific criteria.§ Trends in annual case counts were assessed using linear regression. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.


During 2012–2021, 251 cases were identified in 11 states. A median of 24 cases were reported from these states per year (range = 15 [2020] to 41 [2014]). No significant change in the number of cases was observed during this period (p = 0.21). The median age of infected persons was 39 years (range = 2–92 years); 60% were male (Table 1). No infected persons were reported to be pregnant. Race and ethnicity data were available for 190 (76%) persons; among these, 93% were non-Hispanic White persons.

Reported case counts varied by state, with four states accounting for >75% of all cases (California [33%], Washington [18%], Colorado [14%], and Oregon [12%]). Other states with reported cases included Arizona (9%), Texas (5%), Idaho (4%), Utah (3%), Montana (1%), Nevada (1%), and New Mexico (<1%). Among the 12 states with mandated reporting, no cases were reported in Wyoming. Among 232 (92%) cases with available data on state of residence and exposure, 33 (14%) occurred in out-of-state visitors; among the 210 (84%) cases for which county of the patient’s exposure was available (Figure), 118 (56%) occurred in out-of-county visitors. Epidemiologic links to other cases were documented in 21% of cases; the largest outbreak (11 cases) occurred in Arizona in 2014 (7). Four (2%) cases were attributed to exposures occurring during international travel to Argentina, Canada, Jordan, and Tanzania.

Among 11 reported STRF cases with patient exposures in counties of lower elevations in central Texas, where infections are more likely to be caused by B. turicatae, cave exposures were documented in four. Among 217 cases with patient exposures in other western U.S. states, where infections are more likely to be caused by B. hermsii, a summer peak was observed, with 154 (71%) cases occurring during June–September. Notable exposures documented among 177 patients in these western states included visits to cabins (131, 74%) and camping (15, 8%).

Some clinical data were provided for 207 (82%) patients with reported STRF (Table 2). Fever was documented in 97% of cases; a median of two distinct febrile episodes (range = 1–9)** was reported among febrile patients. Other commonly reported signs and symptoms included headache (63%), myalgias (59%), chills (54%), and nausea or vomiting (45%). Among 211 patients for whom hospitalization data were available, 115 (55%) were hospitalized, including 44% of 36 children aged ≤12 years and 67% of 30 adults aged ≥65 years (Table 1). No deaths were reported.

Laboratory test data were available for 221 (88%) patients; among these, spirochetes were identified by microscopy of peripheral blood smear in 130 (59%). In addition, relapsing fever Borrelia antibodies were detected by serologic testing in 91 (41%) patients, and relapsing fever Borrelia DNA was detected by polymerase chain reaction (PCR) testing in 33 (15%).†† Relapsing fever spirochetes were cultured in four (2%) cases.


The geographic distribution and seasonal pattern of reported STRF have remained relatively constant since the 1990s (8). During 1990–2011, the median annual case count (20) (8) was slightly lower than that during 2012–2021 (24); however, the increase from 1990 to 2021 was not statistically significant (p = 0.84). A large proportion of cases continue to occur in nonresident visitors to areas where the disease is endemic (such as vacationers to mountain cabins); cases in returned visitors who live in areas where STRF is not endemic or reportable would be more likely to be missed by clinicians and public health authorities. Though molecular diagnostic testing has become increasingly available in recent years, microscopic examination of peripheral blood smears remains an important diagnostic test; microscopy is most sensitive when performed during febrile episodes because fever is associated with coincident high levels of spirochetemia.


The findings in this report are subject to at least four limitations. First, surveillance for STRF is likely hindered by underrecognition and underdiagnosis; some state health departments have also noted misdiagnosis of STRF as Lyme disease, given that antibodies to STRF-causing Borrelia spp. can cross-react with some serologic assays for Lyme disease. The emergence of hard tick relapsing fever (HTRF) caused by Borrelia miyamotoi has further complicated accurate diagnosis, particularly in states where both STRF and HTRF might occur, because most serologic and PCR assays do not distinguish between these (9). Second, case ascertainment by state health departments is likely limited by underreporting, because states rely primarily on provider reporting.§§ Third, case ascertainment is inconsistent across states because of differing or absent case definitions. STRF might also occur in states where it is not currently reportable; a very small number of cases have historically been reported from Oklahoma, Kansas, Ohio, and the U.S. Virgin Islands (10). For these reasons, reported cases likely underestimate the true case count. Finally, information on clinical features and exposures was limited to what was obtained by health departments; these data are not collected in all case investigations.

Implications for Public Health Practice

STRF often occurs in clusters because of common exposures; inhabitants and visitors to a soft tick–infested structure can become infected over multiple decades. Unrecognized or unreported cases are missed opportunities for intervention to prevent future exposures. To reduce STRF incidence in the United States, progress in surveillance, prevention, and disease recognition is needed. A regional standardized case definition has been developed by vectorborne disease epidemiologists in several states with endemic disease; broader adoption of this case definition would enhance STRF surveillance. In addition, residents and visitors to areas where STRF is endemic should be educated about how to prevent soft tick bites (most importantly, avoidance of rodent-infested structures and rodent habitats such as caves) and when to seek medical care. Owners of tick- or rodent-infested cabins should be made aware of recommendations for remediation of these structures.¶¶ Clinicians should be aware of the clinical syndrome accompanying STRF, associated exposures, options for diagnostic testing, and public health reporting requirements. Increased awareness of and access to molecular diagnostic testing for symptomatic patients with suspected STRF might improve recognition of cases at different stages of illness. Coordinated improvements in surveillance, prevention, and diagnosis have the potential to prevent morbidity and mortality from STRF in the United States in the next decade.

Corresponding author: Amy M. Beeson,

1Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 2Epidemic Intelligence Service, CDC; 3California Department of Public Health; 4Washington State Department of Health; 5Arizona Department of Health Services; 6Career Epidemiology Field Officer Program, CDC; 7Colorado Department of Public Health and Environment; 8Montana Department of Public Health and Human Services; 9Idaho Department of Health and Welfare; 10Public Health Division, Oregon Health Authority; 11Utah Department of Health and Human Services; 12Texas Department of State Health Services; 13Nevada Department of Health and Human Services; 14New Mexico Department of Health.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

* STRF was not consistently reportable in all 12 states during 2012–2021. In Texas, STRF was removed from the reportable diseases list in 2016 and added back in 2021. In Wyoming, relapsing fevers became reportable in 2012.

Cases were classified as confirmed, probable, or suspected according to each jurisdiction’s case definition.

§ Unclassified cases from states that did not have a case definition in use were reviewed individually. These were included in this case summary if they had laboratory evidence of infection (defined as spirochetes detected on blood smear, relapsing fever Borrelia DNA detected by polymerase chain reaction, positive serologic testing for relapsing fever, or isolation of relapsing fever Borrelia spirochetes in culture) or if they had a clinical syndrome compatible with relapsing fever together with either exposure to soft tick habitat within 2–18 days of symptom onset or an epidemiologic link to a case with laboratory evidence of infection.

45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

** Relapses were defined as occurrences of fever separated by ≥3 days, although information on timing of fevers was incomplete for some patients.

†† Information on Borrelia species was not available, because most laboratory tests do not reliably distinguish between relapsing fever group Borreliae (e.g., between B. hermsii and B. turicatae).

§§ Approximately one third of cases included in this summary (35%) were reported to state health departments through laboratory reporting compared with 58% reported by providers, and this proportion did not change over the 10-year period.



  1. Barbour A. Relapsing fever [Chapter 16]. In: Goodman J, Dennis D, Sonenshine D, eds. Tick-borne diseases of humans. Washington, DC: ASM Press; 2005: 268–91.
  2. CDC. Tickborne diseases of the United States. Tickborne relapsing fever (TBFR). Washington, DC: US Department of Health and Human Services, CDC; 2022.
  3. CDC. Acute respiratory distress syndrome in persons with tickborne relapsing fever—three states, 2004–2005. MMWR Morb Mortal Wkly Rep 2007;56:1073–6. PMID:17947965
  4. Melkert PW. Relapsing fever in pregnancy: analysis of high-risk factors. Br J Obstet Gynaecol 1988;95:1070–2. PMID:3191046
  5. Fuchs PC, Oyama AA. Neonatal relapsing fever due to transplacental transmission of Borrelia. JAMA 1969;208:690–2. PMID:5818572
  6. CDC. Tickborne relapsing fever in a mother and newborn child—Colorado, 2011. MMWR Morb Mortal Wkly Rep 2012;61:174–6. PMID:22419050
  7. Jones JM, Schumacher M, Peoples M, et al. Notes from the field: tickborne relapsing fever outbreak at an outdoor education camp—Arizona, 2014. MMWR Morb Mortal Wkly Rep 2015;64:651–2. PMID:26086637
  8. Forrester JD, Kjemtrup AM, Fritz CL, et al. Tickborne relapsing fever—United States, 1990–2011. MMWR Morb Mortal Wkly Rep 2015;64:58–60. PMID:25632952
  9. Rubio LA, Kjemtrup AM, Marx GE, et al. Borrelia miyamotoi infection in immunocompromised man, California, USA, 2021. Emerg Infect Dis 2023;29:1011–4. PMID:37081591
  10. Dworkin MS, Schwan TG, Anderson DE Jr, Borchardt SM. Tick-borne relapsing fever. Infect Dis Clin North Am 2008;22:449–68, viii. PMID:18755384
TABLE 1. Characteristics of patients with soft tick relapsing fever reported in U.S. states — United States, 2012–2021Return to your place in the text
Characteristic No. of cases (%) No. of patients hospitalized/No. with available hospitalization data (%)
Total 251 (100) 115/211 (55)
Female 99 (39) 52/87 (60)
Male 151 (60) 63/123 (51)
Other or unknown 1 (<1) 0/1 (—)
Age group, yrs
≤12 40 (16) 16/36 (44)
13–18 21 (8) 7/11 (64)
19–64 152 (61) 72/134 (54)
≥65 37 (15) 20/30 (67)
Suspected exposure location
Texas* 12 (5) 6/12 (50)
Western United States 217 (93) 104/187 (56)
International 4 (2) 2/2 (100)

* The suspected etiology of soft tick relapsing fever for most patients with exposure in Texas is Borrelia turicatae based on known pathogen distribution.
Includes Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, and Washington.

Return to your place in the textFIGURE. Cases* of soft tick relapsing fever (n = 210), by county§ of exposure — United States, 2012–2021
The figure is a map of the United States showing cases of soft tick relapsing fever, by county of exposure, during 2012–2021.

* The figure does not show exact location of cases because they were arbitrarily placed within the county of exposure.

Data on county of exposure was not available for all 251 cases included in this report.

§ Mean elevation shown per county.

TABLE 2. Documented signs and symptoms in patients with soft tick relapsing fever (n = 207) — United States, 2012–2021Return to your place in the text
Sign or symptom No. (%)* of patients
Fever (at least one episode) 201 (97)
Headache 130 (63)
Myalgias 123 (59)
Chills 112 (54)
Nausea/Vomiting 94 (45)
Sweats 65 (31)
Fatigue/Malaise 65 (31)
Anorexia 63 (30)
Arthralgias 43 (21)
Cough 28 (13)
Altered mental status 24 (12)
Thrombocytopenia 21 (10)
Rash 20 (10)
Photophobia 14 (7)
Neurologic or ocular symptoms 10 (5)
Abdominal pain 9 (4)

* Among persons with available clinical data; patients could have multiple signs or symptoms.
Reported neurologic or ocular symptoms included uveitis, Bell’s palsy, blurred vision, eye pain, and eye swelling.

Suggested citation for this article: Beeson AM, Kjemtrup A, Oltean H, et al. Soft Tick Relapsing Fever — United States, 2012–2021. MMWR Morb Mortal Wkly Rep 2023;72:777–781. DOI:

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version ( and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to